HR 8205: Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

HR 8205 in plain English: This bill reauthorizes through FY2031 federal programs supporting research and development of treatments for ALS (Lou Gehrig's disease) and other neurodegenerative diseases. It extends grants through the NIH and FDA, and continues a public-private partnership focused on developing and reviewing therapies for these conditions. The bill also adds new safety reporting requirements and directs the FDA to publish a five-year action plan for advancing ALS and rare neurodegenerative disease treatments.

Stated purpose

To reauthorize through fiscal year 2031 the federal programs that fund research and development of treatments for ALS (Lou Gehrig's disease) and other neurodegenerative diseases, and to add new requirements for safety reporting and a published FDA action plan for rare neurodegenerative diseases.

Key points

• Reauthorizes NIH grants for ALS drug research, including for patients ineligible for clinical trials, through FY2031
• Reauthorizes FDA grants for research and development of ALS and other neurodegenerative disease therapies through FY2031
• Continues a public-private partnership between the FDA and NIH to support treatment development and regulatory review
• Requires NIH grantees to promptly report serious and unexpected adverse events from investigational drugs
• Requires the FDA to publish a five-year plan and follow-up report on advancing ALS and rare neurodegenerative disease treatments

Arguments supporters make

• ALS is a fatal disease with very few treatment options, and keeping these research programs funded gives patients their best chance at accessing new therapies before the disease takes their lives.
• Requiring grantees to report safety problems quickly and share efficacy data at renewal makes the program more accountable and protects vulnerable patients enrolled in these studies.
• The FDA action plan requirement holds the agency publicly accountable to a concrete roadmap, which can speed up the path from research to approved treatments for rare diseases that are often overlooked.

Arguments opponents make

• Reauthorizing programs through 2031 commits significant federal funding without a thorough evaluation of whether the existing programs have actually produced effective treatments or represented good use of taxpayer dollars.
• The new safety-reporting and data-disclosure requirements add regulatory burdens on researchers and small biotech companies, potentially slowing down the very research the bill intends to accelerate.
• Focusing federal neurodegenerative disease resources heavily on ALS may come at the expense of patients with other equally devastating rare neurological conditions that lack the same legislative attention.

Tradeoffs

Extending federal investment in ALS research expands access and accountability but requires ongoing public spending and new compliance obligations for researchers; concentrating resources on ALS and select neurodegenerative diseases may mean less flexibility to direct funds toward other emerging medical needs.

Current status in Congress: Passed House.

NewsClear — neutral news & congressional tracking · Bill of the Week